ABVX - Quick Take: On Trinque À Ça! - Part 2 Data & Safety Arrives In-Line, Relieving Pressure on Shares Ahead of FDA Engagement

Research evidence excerpt

ABVX - Quick Take: On Trinque À Ça! - Part 2 Data & Safety Arrives In-Line, Relieving Pressure on Shares Ahead of FDA Engagement

Truist Securities

Equity Research Report June 29, 2026

HEALTHCARE: Biotech Abivax SA (ABVX)

ABVX - Quick Take: On Trinque À Ça! - Part 2 Data & Safety Gregory Renza, M.D.

212-419-4617 Arrives In-Line, Relieving Pressure on Shares Ahead of FDA

Gregory.Renza@truist.com Engagement

Anish Nikhanj, Ph.D.

212-326-3106 This afternoon, ABVX disclosed the recently awaited maintenance Part 2 data and

Anish.Nikhanj@truist.com hosted a mgmt call featuring two UC KOLs - with safety in focus, we note data coming

in-line of our expectations, and the mid-range of previously given benchmarks -

Supawat Thongthip, Ph.D. which in the context of the flurry of recent obe' updates over the month of June,

212-401-4429 should be a welcome adjunct to program perception, the building clinical profile,

Supawat.Thongthip@truist.com and ABVX shares overall. See our views on Part 1 data: Catalyst: Part Deux: ABTECT

Maintenance Update, Part 2 Data Set by End-of-Month; We See Easing to Volatility; see our

safety analysis and benchmark work coming into today's disclosure: Donner Le La: Investor

Current Price (Jun. 29, $96.15 Conversations & Our Safety Analysis Set the Tone Into Part 2 Data; Finding a Groove. Into 2026) the continued eventful 2026 catalyst path with FDA proceeding in focus, we maintain

our $135 PT and Buy rating.

Stock Rating BUY

Unchanged Ph.III ABTECT maintenance Part 2 data delivered meaningful benefit in a refractory

(and challenging) population. Part 2 data, featuring supplemental safety-primary arm,

Price Target $135.00 enrolled induction non-responders treated through wk 52 along with Part 1 responders who

Unchanged relapsed and rolled to OL 50mg.